Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(LY411575; LY 411575)
LY-411575 Chemical Structure
|Product name: LY-411575|
|Cat. No.: HY-50752|
LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch clevage with IC50 of 0.39 nM.
IC50 value: 0.078 nM/0.082 nM (membrane/cell-based) 
in vitro: LY-411575 inhibits γ-secretase which can be assessed by the substrates like amyloid precursor protein (APP) and Notch S3 cleavage . LY-411575, which blocks Notch activation, results in apoptosis in primary and immortalized KS cells .
in vivo: 10 mg/kg oral dose of LY-411575 decreases brain and plasma Aβ40 and -42 dose-dependently.  LY-411575 reduces cortical Aβ40 in young (preplaque) transgenic CRND8 mice (ED50 ≈ 0.6 mg/kg) and produces significant thymus atrophy and intestinal goblet cell hyperplasia at higher doses (>3 mg/kg). The therapeutic window is similar after oral and subcutaneous administration and in young and aged CRND8 mice. Both the thymus and intestinal side effects are reversible after a 2-week washout period. Three-week treatment with 1 mg/kg LY411575 reduces cortical Aβ40 by 69% without inducing intestinal effects, although a previously unreported change in coat color is observed .
|M.Wt||479.48||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO: 95 mg/mL, H2O: <1 mg/mL
|1 mg||5 mg||10 mg|
|1 mM||2.0856 mL||10.4280 mL||20.8559 mL|
|5 mM||0.4171 mL||2.0856 mL||4.1712 mL|
|10 mM||0.2086 mL||1.0428 mL||2.0856 mL|
|Product Name||Sponsor Only||Condition||Start Date||End Date||Phase||Last Change Date|
|LY-411575||Eli Lilly & Co||Alzheimers disease||31-DEC-09||30-APR-11||Phase 3||16-AUG-11|
|Eli Lilly & Co||Alzheimers disease||31-MAR-08||31-MAY-11||Phase 3||04-OCT-13|
|Eli Lilly & Co||Alzheimers disease||31-OCT-05||31-DEC-06||Phase 2||24-APR-12|
|Eli Lilly & Co||Alzheimers disease||31-JUL-06||30-SEP-07||Phase 1||18-JUN-09|
|Eli Lilly & Co||Alzheimers disease||30-SEP-08||30-APR-11||Phase 3||24-AUG-11|
. Wong GT, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004 Mar 26;279(13):12876-82.
. Hyde LA, et al. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J Pharmacol Exp Ther. 2006 Dec;319(3):1133-43.
Avagacestat (BMS-708163) is a potent, selective, orally bioavailable (gamma)-secretase inhibitor of A(beta)40 and A(beta)42 with IC50 of 0.3 nM and 0.27 nM, demonstrating a 193-fold selectivity against Notch.
CHF5074 is a novel (gamma)-secretase modulator, reduces A(beta)42 and A(beta)40 secretion, with an IC50 of 3.6 and 18.4 (mu)M, respectively.
DAPT(GSI-IX) is an inhibitor of (gamma)-secretase; DAPT causes a reduction in A(beta)40 and A(beta)42 levels in human primary neuronal cultures (IC50 values are 115 and 200 nM for total A(beta) and A(beta)42 respectively) and in brain extract, cerebrospinal fluid and plasma in vivo.
E 2012 is a potent (gamma)-secretase modulator.
(gamma)-secretase inhibitior-1 is a gamma-secretase modulator, (gamma)-secretase inhibitior-1 is useful for Alzheimer(acute)s disease.
gamma-secretase modulator 2 is a potent and selective (gamma)-secretase modulator for treatment of Alzheimer(acute)s disease.
gamma-secretase modulator 3 is a gamma-secretase modulator.
L-685458 is a potent inhibitor of Amyloid (beta)-Protein precursor (gamma)-secretase activity with IC50 of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested.
MK-0752 is a moderately potent (gamma)-secretase inhibitor, which reduces A(beta)40 production with IC50 of 5 nM.
PF-3084014 is a novel (gamma)-secretase inhibitor that reduces amyloid-beta (Abeta) production with an in vitro IC(50) of 1.2 nM (whole-cell assay) to 6.2 nM (cell-free assay).